Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Purpose

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Condition

  • Hematopoietic Stem Cell Transplant

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult 18 years or older - Referred for HSCT evaluation - Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes) - Able to ambulate unassisted - Ability to understand and the willingness to sign a written informed consent - Ability to use Polar Flow heart rate application

Exclusion Criteria

  • Severe anemia (hemoglobin <7 gm/dl) - Untreated high-risk coronary artery disease (left main, triple vessel disease) - Severe aortic stenosis - Recent fracture as assessed via self-report - Gross balance deficits - Severe pain with basic movement - Unable to ambulate unassisted or exercise - NYHA class IV heart failure - Adults unable to give consent, pregnant women, and prisoners are excluded from this study.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cardio-oncology program 		The cardio-oncology program consists of a multimodal approach, which includes individualized exercise prescription following a detailed CV assessment and medical management of CV risk factors occurring over 8 weeks.
  • Other: Cardio-oncology program
    Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)

Recruiting Locations

University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 48109
Contact:
Cancer AnswerLine
800-865-1125
CancerAnswerLine@med.umich.edu

More Details

NCT ID
NCT05945121
Status
Recruiting
Sponsor
University of Michigan Rogel Cancer Center

Study Contact

Cancer AnswerLine
1-800-865-1125
CancerAnswerLine@med.umich.edu

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center